Verition Fund Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
Verition Fund Management's AXSM Position: Q3 2026 in Review
Verition Fund Management reduced its Axsome Therapeutics (AXSM) stake by 33% in Q3 2026, selling an estimated $435K and leaving 4,000 shares worth $738K. The position accounts for ﹤0.01% of the portfolio, ranked #1508.
Verition Fund Management first reported a position in AXSM in Q1 2020 and has held it in 9 quarters since. The position peaked at $3.38M in Q1 2025. 466 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- Verition Fund Management held 4,000 shares of Axsome Therapeutics worth $738K as of Q3 2026.
- Verition Fund Management sold 2,000 Axsome Therapeutics shares in Q3 2026, an estimated $435K.
- Axsome Therapeutics made up ﹤0.01% of Verition Fund Management's portfolio in Q3 2026, its #1508 holding.
- Verition Fund Management first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 9 quarters since.
- Verition Fund Management's Axsome Therapeutics position peaked at $3.38M in Q1 2025.
- 466 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.